Cytoprotective effects of IAPs revealed by a small molecule antagonist
Open Access
- 16 January 2009
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 417 (3) , 765-771
Abstract
Deregulated expression of members of the IAP (inhibitor of apoptosis) family has been identified in a wide variety of neoplastic cells, and synthetic IAP antagonists represent a promising novel class of chemotherapeutic agents. Early work focused on the ability of these compounds to block the caspase-inhibitory function of XIAP (X-linked IAP). However, recent studies have shown that IAP antagonists, although primarily designed to target XIAP, trigger ubiquitin-mediated degradation of two related proteins, c-IAP (cellular IAP) 1 and c-IAP2, and through this process potentiates the death of tumour cells via autocrine cellular-signalling pathways. In this context, the relative contribution of XIAP as a target of this class of compounds is unclear. In the present study, we examine the involvement of XIAP using a recently described synthetic IAP antagonist, AEG40730, and through comparison of a human XIAP-depleted tumour cell line with its isogenic wild-type control line. Treatment with nanomolar concentrations of AEG40730 resulted in the loss of both XIAP and c-IAP1 proteins, albeit with different kinetics. Although XIAP-deficient HCT116 cells retained some sensitivity to external apoptotic stimuli, the results suggest that IAP antagonists, such as AEG40730, exert their apoptosis-enhancing effects through XIAP in addition to the c-IAPs. These results indicate that IAP antagonists can target multiple IAPs to augment distinct pro-apoptotic signalling pathways, thereby revealing the potential for these compounds in cancer therapy and underscoring the promise of IAP-targeted therapies.Keywords
This publication has 36 references indexed in Scilit:
- IAPs: What's in a Name?Molecular Cell, 2008
- Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced ApoptosisCancer Cell, 2007
- On the TRAIL to therapeutic intervention in liver diseaseHepatology, 2007
- Resistance of Cancers to Immunologic Cytotoxicity and Adoptive Immunotherapy via X-Linked Inhibitor of Apoptosis Protein Expression and Coexisting Defects in Mitochondrial Death SignalingCancer Research, 2006
- APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapyFrontiers in Bioscience-Landmark, 2006
- X-Linked Inhibitor of Apoptosis Protein (XIAP) Is a Nonredundant Modulator of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)- Mediated Apoptosis in Human Cancer CellsCancer Research, 2004
- The Hallmarks of CancerCell, 2000
- Proteases to die forGenes & Development, 1998
- An Induced Proximity Model for Caspase-8 ActivationJournal of Biological Chemistry, 1998
- Apoptosis: Telling cells their time is upCurrent Biology, 1996